Attovia Therapeutics Inc. (NASDAQ:ATTO) opened trading with a significant gain, rising 24% from its IPO price on its first day as a public company. The clinical-stage biopharmaceutical firm had priced 17 million shares at $17 each, raising $289 million in the offering.
Shares began trading in New York at $21 apiece, above the $17 IPO price, putting the company's implied market value at nearly $904 million based on outstanding shares disclosed in its filings.
The company granted the syndicate a 30-day option to buy up to an additional 2.55 million shares at the IPO price, less underwriting discounts and commissions. The offering is expected to close on August 6, 2026, subject to the satisfaction of customary closing conditions.
Attovia's pipeline and intellectual property rest on a technology platform and patents licensed from Alamar Biosciences Inc., a company known for medical devices that focus on protein study and disease detection. Alamar established Attovia as a separate entity in 2023 and continues to hold an investment stake.
Alamar itself carried out an April IPO in which it raised $219.9 million, and its shares have appreciated by nearly 70% since their market debut, according to the company information cited in Attovia's filings.
Management enlisted several firms to run the book for the transaction. Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets are acting as joint book-running managers. LifeSci Capital is listed as a passive book-running manager for the offering.
Context and implications
The market's positive reception on debut reflects investor appetite for new listings within the clinical-stage biotech sector. The immediate uplift in market value follows the mechanics of the offering: a fixed pricing of shares, a greenshoe-style option for additional volume, and continuing ties to an established medical-device developer through licenses and ownership.
Details on the company's drug candidates or clinical milestones beyond the licensing arrangement were not included in the provided materials.